[A18-59] Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Last updated 22.03.2019
Commission awarded on 24.09.2018 by the Federal Joint Committee (G-BA).
Adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection
Advantage in overall survival and recurrence, disadvantages in side effects; indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A17-17||Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A15-39||Dabrafenib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A13-35||Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)||Commission completed|
|G19-05||Dabrafenib (melanoma) - Addendum to Commission A18-59||Commission completed|